The alcohol industry is stepping into the cannabis debate again—this time by lobbying Congress to impose tighter federal regulations on hemp-derived cannabinoid products like Delta-8 THC, Delta-10, and HHC. The move highlights growing concerns over competition, public health, and regulatory confusion in the rapidly expanding hemp market, but also raises questions about the motives of a competing industry trying to influence cannabis policy.
In a letter to key members of Congress, the Wine and Spirits Wholesalers of America (WSWA) and the Distilled Spirits Council of the United States (DISCUS) urged lawmakers to create a national regulatory framework for intoxicating hemp-derived cannabinoids. These compounds are legally sold under the 2018 Farm Bill, which legalized hemp and its derivatives as long as they contain less than 0.3% Delta-9 THC by dry weight. However, manufacturers have since developed alternative cannabinoids using chemical processes, resulting in potent products that are not explicitly banned under current federal law.
Delta-8 THC, one of the most popular of these compounds, produces mild psychoactive effects and is sold widely across the U.S. in vape cartridges, gummies, and tinctures—even in states that haven’t legalized marijuana. Because these products often bypass the strict testing and safety requirements that apply to regulated cannabis or alcohol, critics say consumers are at risk of exposure to mislabeled or contaminated products.
The alcohol industry claims that regulating these hemp-derived cannabinoids is a matter of public health. But cannabis advocates point out that many of these same alcohol groups have opposed cannabis legalization in the past, and now appear concerned about market competition from a fast-growing sector that operates outside the traditional liquor distribution model.
Retail sales of hemp-derived cannabinoids have surged in recent years, especially in convenience stores, smoke shops, and online retailers. According to industry analysts, the market for Delta-8 alone was worth nearly $2 billion in 2023. Unlike state-regulated cannabis, these products are often cheaper and more accessible—particularly in prohibition states—creating strong consumer demand and rapid growth.
The patchwork of state laws has only added to the confusion. Some states, like Colorado and New York, have banned synthetic cannabinoids altogether, while others like Florida and Texas have tried to regulate them with mixed success. Without clear federal rules, enforcement is inconsistent, and both consumers and businesses are left in legal limbo.
Now, with the 2023 Farm Bill still under discussion in Congress, lobbying efforts from the alcohol industry could influence how hemp-derived cannabinoids are addressed in the next version of the law. Lawmakers may consider setting potency limits, requiring safety testing, or establishing age restrictions on sales—similar to how alcohol and tobacco are regulated.
Supporters of regulation say a national framework could improve safety and consumer trust. But critics warn that overly strict rules—especially those pushed by competing industries—could crush innovation and shut down small businesses that have thrived under the current model.
The conversation now turns to whether regulation will be shaped by science and public health—or by the economic interests of industries trying to protect their market share.
For more on topics like these, check this link out BRAZIL WEIGHS MANDATORY DRUG TREATMENT AFTER SUPREME COURT DECRIMINALIZES CANNABIS POSSESSION
